<DOC>
	<DOCNO>NCT01614899</DOCNO>
	<brief_summary>The study evaluate efficacy safety SM-13496 compare placebo patient schizophrenia .</brief_summary>
	<brief_title>A Phase III Study SM-13496 ( Lurasidone HCl ) Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Patient meet DSMIVTR criterion schizophrenia . Patient age 18 74 year informed consent . Patient understand objective , procedure , possible benefit risk study provide write voluntarily consent participate study Patient history neuroleptic malignant syndrome , water intoxication , paralytic ileus . Patient Parkinson 's disease . Patient history complication malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>